Clinical Ink purpose-built and deployed the electronic study environment in just 15 business days, including the study's full schedule of assessments, a full complement of edit checks and logic, and complete user acceptance testing.
The flexibility of the Lumenis technology platform and its ability to be adapted and deployed quickly have minimized the timeline for this 300-patient, 36-site study.
The drug under investigation is a novel intravenous anti-inflammatory.
This new molecular entity is a granulocyte macrophage colony stimulating factor antagonist that already has Phase I safety data from a clinical trial in volunteers and patients with ankylosing spondylitis.
Clinical Ink, a global clinical technology company, offers data certainty from source to submission.
Our Lumenis eSource clinical technology and configurable direct data capture, eCOA, ePRO, and eConsent modules, a suite of solutions for capturing and integrating electronic data from sites, clinicians, and patients at its source, naturally enhance your clinical trial workflow by reducing manual labor, providing anytime, anywhere data access, and saving resources as your trials progress.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval